Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2021

Dimou Anastasios, Grewe Paul, Sidney John, Sette Alessandro, Norman Paul J, Doebele Robert C

Abstract excerpt

INTRODUCTION: Cancer-associated mutations have the potential to generate neoantigens and elicit CD8-positive T-cell-dependent adaptive immune responses. There are currently no reports of CD8-positive T-cells with specificity for neoepitopes generated by EGFR mutations, which are driver oncogenes in a subset of patients with lung cancer. METHODS: We used NETMHCpan 4.0 to identify putative protective human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Peptides

Source

Open in PubMed Open full text

Identifiers

PMID: 32927123
DOI: 10.1016/j.jtho.2020.08.023
PMCID: PMC7797166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.PMID 32927123Read ↗

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designSemantic proximity Read ↗

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver MutationsSemantic proximity Read ↗

Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancerSemantic proximity Read ↗

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.Semantic proximity Read ↗

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.Semantic proximity Read ↗

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.Semantic proximity Read ↗

Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinomaSemantic proximity Read ↗

Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.Semantic proximity Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer.Semantic proximity Read ↗

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.Semantic proximity Read ↗

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.